Complix and MSD team up for cell-penetrating alphabodies
Posted: 6 January 2016 | Victoria White | No comments yet
Complix will use its proprietary Alphabody platform to deliver cell-penetrating alphabodies against up to two intracellular cancer targets of interest to MSD…
Complix has entered into a strategic drug discovery collaboration with MSD to develop cell-penetrating alphabodies for the treatment of cancer.
Cell-penetrating alphabodies are a revolutionary class of small proteins engineered to bind to a variety antigens. Data available show that cell-penetrating alphabodies have the potential to address a wide range of disease targets, including intracellular targets that are difficult for current therapies to reach. To date, Complix has shown that cell-penetrating alphabodies have the unique ability to enter tumour cells effectively and selectively modulate intracellular protein-to-protein interactions, which play a key role in the initiation and progression of a broad range of cancers. Cell-penetrating alphabodies are also able to enter many different types of tumour cells and remain stable within the tumour tissue for up to 24 hours post administration.
Collaboration a ‘major corporate milestone’ for Complix
Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deliver cell-penetrating alphabodies against up to two intracellular cancer targets. MSD will fund related research activities and has an option to the exclusive, worldwide rights for any of the resulting compounds. Complix is entitled to receive an upfront payment and potential development milestones of up to $280 million, as well as tiered royalties.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
Commenting on the announcement, Dr Mark Vaeck, CEO of Complix, said: “This collaboration with MSD is a major corporate milestone for Complix and highlights the potential of our unique cell-penetrating alphabody platform, which we believe will deliver game changing biotherapeutics for the treatment of cancer. With such a high quality partner, I am confident that Complix will be able to rapidly progress the development of cell-penetrating alphabody drug candidates that we will generate against cancer targets of interest to MSD. I am very much looking forward to working with the team of MSD.”
Related topics
Drug Discovery
